EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis

Anna Negroni, Luisa Pieroni iD, Noemi Fiaschini, Francesca Palone, Mariateresa Mancuso iD, Roberta Vitali iD

PROTEOMICS – Clinical Applications · 2026-07 · 20 (4)

DOI: 10.1002/prca.70047 ↗

At a glance

Journal article in PROTEOMICS – Clinical Applications, published online on 2026-05-29. Written by Anna Negroni and 5 co-authors. Institution: Division of Biotechnologies, ENEA, Casaccia Research Center, Rome, Italy. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Proteomics, Feces. 57 references. The full text is freely available (open access, CC BY 4.0). Funded by: Project ECS 0000024 Rome Technopole, - CUP B83C22002820006, National Recovery and Resilience Plan (NRRP), Mission 4, Component 2 Investment 1.5, funded from the European Union - NextGenerationEU.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and aims Non‐alcoholic Fatty Liver Disease (NAFLD) affects about a quarter of the world's population. Liver biopsy remains the gold standard for diagnosing the progressive form of NAFLD called Non‐alcoholic Steatohepatitis (NASH) but it is invasive, prone to sampling errors and observer variability, and impractical for widespread use. Fecal non‐invasive biomarkers have emerged as a new approach to diagnose, stage, and monitor NAFLD over time.

Methods

Proteomic analysis was performed using Liquid Chromatography‐Mass Spectrometry (LC‐MS/MS) in fecal samples derived from mice fed with high fat and sugar diet representing NAFLD model and with the addition of 5 cycles of dextran‐sulphate in drinking water to induce a NASH.

Results

Qualitative and quantitative different protein profiles resulted in a comparison between the three groups of mice. An enrichment analysis of differentially expressed proteins explores the molecular pathways involved. A selection of the most significant modulated proteins between groups was performed. The proteins Transthyretin, Kallikrein1 and Trefoil Factor 3 were validated by ELISA.

Conclusion

Our exploratory discovery study identified several proteins that, alone or in combination, enable a good separation between NASH, NAFLD and healthy mice, highlighting their potential as key targets for future research.

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseProteomicsFecesAnimalsBiomarkersMiceMaleMice, Inbred C57BL

Author keywords

fatty liverfecal proteinsnon‐invasive biomarkersproteomicssteatohepatitis

Substances

Biomarkers

Authors and institutions

  • Division of Biotechnologies, ENEA, Casaccia Research Center, Rome, Italy.
  • Departmental Faculty of Medicine and Surgery, UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.
  • IRCCS San Camillo Hospital, Venice, Italy.
  • Nanofaber S.r.l., Rome, Italy.
  • Department For Sustainability, Division Sustainable Materials, ENEA, Casaccia Research Centre, Rome, Italy.

ORCID profiles: Luisa Pieroni, Mariateresa Mancuso, Roberta Vitali

Funding

  • Project ECS 0000024 Rome Technopole, - CUP B83C22002820006
  • National Recovery and Resilience Plan (NRRP), Mission 4, Component 2 Investment 1.5, funded from the European Union - NextGenerationEU

Cite

APA

Negroni, A., Pieroni, L., Fiaschini, N., Palone, F., Mancuso, M., & Vitali, R. (2026). Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis. PROTEOMICS – Clinical Applications, 20(4). https://doi.org/10.1002/prca.70047

Vancouver

Negroni A, Pieroni L, Fiaschini N, Palone F, Mancuso M, Vitali R. Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis. PROTEOMICS – Clinical Applications. 2026;20(4). doi:10.1002/prca.70047

BibTeX
@article{Negroni2026,
  author = {Negroni, Anna and Pieroni, Luisa and Fiaschini, Noemi and Palone, Francesca and Mancuso, Mariateresa and Vitali, Roberta},
  title = {Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2026},
  volume = {20},
  number = {4},
  doi = {10.1002/prca.70047}
}
Start for free →